CJC-1295 (with DAC)

A modified growth hormone releasing hormone (GHRH) analog with a Drug Affinity Complex that binds to albumin, extending its half-life to approximately 6-8 days. This allows for sustained GH elevation with less frequent dosing compared to non-DAC variants.

• Binds to GHRH receptors on anterior pituitary somatotrophs to stimulate GH release
• Drug Affinity Complex binds serum albumin, preventing rapid degradation by DPP-IV
• Promotes pulsatile GH secretion over an extended period

• Active malignancy or history of cancer
• Pregnancy or breastfeeding
• Diabetic retinopathy

Store at 2–8°C (36–46°F) for up to 3 months. For long-term storage, keep at -20°C (-4°F). Once reconstituted, refrigerate and use within 28 days.

CJC-1295 with DAC has been studied in Phase II clinical trials demonstrating dose-dependent increases in GH and IGF-1 levels sustained over weeks. Research showed 2-10 fold increases in mean GH concentrations after a single injection. Development was paused due to safety concerns in one trial, though the compound remains widely studied in research settings.